Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Double Blind Placebo-controlled Clinical Study : Effect of IBSIUM on the Improvement of Gastro-intestinal Disorders Associated to the Irritable Bowel Syndrome (IBS) With C Phenotype (Predominant-constipation)

NCT03150212 is registered in ClinicalTrials.gov with Lesaffre International as lead sponsor.

NCT NCT03150212
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03150212 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Double Blind Placebo-controlled Clinical Study : Effect of IBSIUM on the Improvement of Gastro-intestinal Disorders Associated to the Irritable Bowel Syndrome (IBS) With C Phenotype (Predominant-constipation)
Lead sponsor
Lesaffre International
Phase
Not applicable
Overall status
Completed
Start date
March 20, 2017
Completion date
May 9, 2019
Enrollment
456 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

constipation-predominant irritable bowel syndrome